Latest research on Atorvastatin

Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.

Latest findings

Camphene, Mevinolin, Atorvastatin and U18666A were from Sigma-Aldrich. [source, 2016]
On day 7, the cells were incubated for 24 h in the presence of vehicle or compounds (camphene, Mevinolin, Atorvastatin, F1394 or U18666A) at the indicated concentrations in fresh DMEM containing 10% LPDS. [source, 2016]
The well known HMG-CoA reductase inhibitors, Mevinolin and Atorvastatin, were used as positive controls to inhibit cholesterol and cholesterol ester biosynthesis in hepatocytes. [source, 2016]
As it was expected Mevinolin and Atorvastatin caused a dramatic decrease in cholesterol and cholesterol ester levels. [source, 2016]
To analyze and quantify the levels of neo-synthesized lipids, HepG2 cells were incubated with camphene, Mevinolin and Atorvastatin and the incorporation of [14C]-acetate into cholesterol, fatty acids and triglycerides was determined. [source, 2016]
As it was expected, the statins, Mevinolin and Atorvastatin, nearly abolished [14C]-acetate conversion into cholesterol biosynthesis from the precursor [14C]-acetate as they decreased newly synthesized cholesterol levels by 97% and 90% respectively (p<0.001). [source, 2016]
Interestingly, Mevinolin and Atorvastatin increased the amount of newly synthesized triglycerides by 26% (p<0.05) and 20% (p<0.05) respectively. [source, 2016]
Again, there were no significant changes between the effects of Mevinolin and Atorvastatin. [source, 2016]
Mevinolin and Atorvastatin had also no effect on the incorporation of [14C]-oleate into the triglyceride fraction (results not shown). [source, 2016]
These results are in agreement with previous studies showing that statins, Atorvastatin and Mevinolin, increased SREBP-2 expression but not SREBP-1 [56]. [source, 2016]